Know Cancer

or
forgot password

Early Detection Biomarkers for Mesothelioma Among Asbestos and Vermiculite Exposed Populations


N/A
25 Years
80 Years
Open (Enrolling)
Both
Malignant Mesothelioma, Pulmonary Complications

Thank you

Trial Information

Early Detection Biomarkers for Mesothelioma Among Asbestos and Vermiculite Exposed Populations


OBJECTIVES:

- Identify patients with known asbestos exposure at early stages of disease development
(i.e., indolent premalignant pleural plaques and fibrosis vs malignant pleural
mesothelioma).

- Determine the expression levels of tumor-associated proteins in these patients.

- Analyze samples of serum and pleural effusions obtained from these patients.

- Determine the proteomic profile of samples obtained from these patients.

- Determine the molecular mechanisms associated with the regulation of the extracellular
matrix microenvironment proteins (e.g., osteonectin, intelectin, or matrix
metalloproteins) involved in disease onset and progression.

OUTLINE: This is a multicenter study.

Patients undergo collection of body cavity fluid, including pleural effusion, and blood.
Specimens, including fresh frozen malignant pleural mesothelioma tumor tissue, if available,
are analyzed for proteomic profile, gene expression profile, and tumor-associated protein
expression levels.

PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Exposure to vermiculite or asbestos insulation

- Symptomatic or nonsymptomatic exposure-related disease

- Seen at a clinic in Libby, Montana (CARD Clinic) or Michigan (COEM)

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Identification of potential drug targets for therapeutic strategies to treat asbestos fiber-related diseases

Outcome Time Frame:

At time of analysis

Safety Issue:

No

Principal Investigator

Anil Wali, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Barbara Ann Karmanos Cancer Institute

Authority:

United States: Federal Government

Study ID:

CDR0000518348

NCT ID:

NCT00897247

Start Date:

January 2007

Completion Date:

Related Keywords:

  • Malignant Mesothelioma
  • Pulmonary Complications
  • malignant mesothelioma
  • pulmonary complications
  • Mesothelioma

Name

Location

Barbara Ann Karmanos Cancer InstituteDetroit, Michigan  48201